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Mesenchymal stem cells (MSC) mediate their immunosuppressive effects via a variety of mechanisms. One of these
mechanisms involves the induction of macrophages with immunomodulatory capacities. This effect of MSC may be
exploited when MSC are used as a cell therapeutic product. Furthermore, MSC are resident in tissues where they
may locally target infiltrating macrophages to adapt more regulatory properties. The present review discusses the
interaction between MSC and macrophages, the induction of MSC-educated macrophages, how these cells position
between other immune regulatory cells, and how they may be used in the clinic.Introduction
Mesenchymal stem cells (MSC) are stromal cells with
potent regenerative and immunomodulatory properties
[1,2]. They are found in multiple tissues, including bone
marrow and adipose tissue [3] and are relatively easy to
isolate and expand in culture. Their capacity to differen-
tiate into multiple cellular lineages and their trophic
effects on other progenitor cells has initiated interest in
the use of these cells for regenerative therapy [4-6].
However, analysis of the mechanisms involved in the
reparative effects of MSC indicates that many of these
effects may in fact relate to the immunomodulatory
properties of MSC. It has been demonstrated that MSC
ameliorate acute graft vs. host disease [7,8], reduce the
progression of kidney fibrosis by modulation of the early
inflammatory response after injury [9,10], and in experi-
mental models show promise as a therapeutic treatment
of immunological diseases including arthritis [11], hepa-
titis [12], and organ transplantation [13,14].
MSC have the capacity to modulate the immune sys-
tem via a plethora of mechanisms. They secrete anti-
inflammatory factors such as TGF-β and hepatocyte
growth factor [2], they inhibit lymphocyte proliferation
via the expression of indoleamine 2, 3-dioxygenase
(IDO) [15], and they express inhibitory co-stimulatory
molecules such as programmed death ligand 1 (PD-L1)
and TNF-related apoptosis-inducing ligand (TRAIL)
[16,17]. In addition, MSC modulate the immune system
via indirect mechanisms by inducing immune cells to* Correspondence: elke.eggenhofer@ukr.de
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cells in vitro and in vivo [14,18] and affect the differenti-
ation and function of dendritic cells [19]. In recent years
it has become clear that MSC also regulate the function
of macrophages. Co-culture with MSC induces macro-
phages to adapt an enhanced regulatory phenotype via
expression of increased levels of IL-10, reduced levels of
TNF-α and IL-12, low co-stimulatory molecule CD86
and HLA class II while showing higher phagocytic activ-
ity [20,21]. This effect of MSC is at least partially
mediated by soluble mechanisms and prostaglandin E2
(PGE-2) has been indicated to be one of the factors
involved [21].
The question is whether the in vitro effects of MSC on
macrophages are operational in vivo. There is evidence
that MSC infusion leads to increased levels of regulatory
type monocytes/macrophages in the circulation [22].
This effect is accompanied by an increase in the abun-
dance of regulatory macrophages present within
inflamed tissue [22]. Furthermore, it has been shown
that locally administered MSC attract macrophages and
turn them into a regulatory phenotype [21,23]. Thus
in vivo administered MSC appear to have a similar effect
on macrophages as their in vitro counterparts. The
mechanisms involved, however, may be very different.
There is accumulating evidence that, after administration,
MSC are short-lived (Eggenhofer et al., in press). As tran-
siently present MSC may themselves be incapable of se-
creting sufficient regulatory macrophages inducing
factors, additional mechanisms may be important. Indeed,
it has been demonstrated that the phagocytosis of dead
MSC by macrophages induces them to adapt a more re-
generative and immunomodulatory function [24]. ThisioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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phages function through initiating phagocytosis, while
resident MSC that are around for a much longer period of
time may modulate macrophages via the secretion of
immunomodulatory factors and expression of cell surface
molecules. In this respect it is interesting that throughout
all tissues MSC are virtually ubiquitous. Tissue-resident
MSC have the full capacity to locally induce regulatory
macrophages. Studies into the influence of MSC on
macrophages behavior are therefore relevant to assess-
ments of MSC as a cell therapeutic product and also to
examine the potentially exploitable effects of tissue-
resident MSC.
Generation of MSC-educated macrophages (MSC-Mo)
In the past, research to the immunomodulatory effect of
MSC focused on the interactions of MSC with T-lym-
phocytes, B-lymphocytes, NK cells, and dendritic cells,
but recently the effect of MSC on the cells of monocytic
lineages, specifically macrophages, has attracted increas-
ing attention. It is well known that MSC can generate an
immunoregulatory type of macrophages in vivo [23].
Furthermore, it has been shown that MSC can also
induce a regulatory macrophage population in vitro
[20,21].
Recent studies have demonstrated the potential of MSC
to educate macrophages to adapt an anti-inflammatory/
immune suppressive phenotype. A number of studies
allowed direct contact between MSC and macrophages
in vitro [20,21]. However, other experiments have indi-
cated that MSC can modulate macrophages via soluble
factors in a transwell system [20].
After co-culturing with MSC, peripheral blood mono-
cytes derived macrophages (Mo) can be described as a
novel type of alternatively activated macrophages (MSC-
Mo) [20]. These MSC-Mo remain adherent to plastic
and keep a Mo morphology. However, an increased
number of Mo can be observed due to the trophic fac-
tors secreted by MSC (Figure 1A). They express higher
levels of CD206, which is known to be a marker of alter-
natively activated macrophages and found on other types
of anti-inflammatory macrophages as well [25]. Func-
tionally, MSC-Mo display higher phagocytic activity
compared to Mo. Moreover, these cells show increased
production of anti-inflammatory IL-10 and IL-6, while
their production of pro-inflammatory cytokines like IL-
12 and TNFα is decreased (Figure 1B). Typically, alter-
natively activated macrophages are known to promote
Th2 type of responses and secrete less pro-inflammatory
cytokines (P. Riquelme: The ONE Study workshop
2012). However, these macrophages retain high levels of
inflammatory cytokine production, such as TNF-α and
IL-6 [26]. Based on those findings, MSC-Mo (IL-10high,
IL-12low, IL-6high, and TNF-αlow) are defined as anovel type of alternatively activated population of
macrophages distinct from previously reported macro-
phages [20].
Application of MSC-Mo in the clinic
To date, MSC from adipose tissue or bone-marrow are
used in several clinical trials in the treatment of a variety
of clinical conditions such as graft vs. host disease [7,8],
myocardial infarction [27], ischemic stroke [28], Crohn’s
disease [29,30], diabetes mellitus [31], and acute graft
rejection in organ transplantation [32,33]. These osten-
sibly dissimilar clinical conditions share the role of
inflammation in their pathogenesis. Macrophages play a
crucial role in not only the initiation but also the con-
tinuation of inflammatory processes. To activate macro-
phages in an alternative way by MSC may reduce
inflammation and could modulate immune responses,
which is of great therapeutic interest. Many groups and
regulatory agencies favor the use of autologous cell ther-
apy to avoid immune recognition. However, isolation,
cultivation, and expansion of MSC to a clinical relevant
dose normally can require several weeks and is not com-
patible with the treatment schedules of many conditions,
particularly in the case of organ transplantation. Gener-
ation of MSC-Mo could be achieved by collection of
monocytes through leukapheresis, followed by co-
cultivation with a universal source of third party MSCs.
Using this strategy a sufficient amount of autologous
MSC-Mo could be prepared within a few days in a sim-
ple and clinical feasible fashion.
However, (pre-)clinical proof of concept studies with
MSC-Mo have yet to be conducted and many questions
remain concerning dosage and timing especially in the
context of solid organ transplantation. Furthermore, a
broader understanding of the potential role of MSC in
situ and their influence on the generation of MSC-Mo
could lead to the development of therapy whereby MSC
are used as inducers of regulatory Mo in vivo. MSC
reside in almost all tissue and will encounter infiltrat-
ing Mo in case of inflammation (Figure 2). MSC may
thus locally affect the function of Mo and be capable
of modulating immune responses in tissues. New therap-
ies may therefore be designed that target tissue MSC
to become activated (for example, mimicking local
inflammation to create pro-inflammatory micromilieu by
injection of pro-inflammatory cytokines) in order to
stimulate infiltrating Mo to adapt a regulatory phenotype
and function.
Positioning of MSC-Mo between immune regulatory cells
MSC-Mo belong to a class of myeloid-derived suppres-
sor cells. These cells share a myeloid origin and immune
regulatory capacity, but are otherwise a heterogeneous
population of cells. They are induced from immature
Figure 1 Generation of MSC-educated macrophages (MSC-Mo). (A) Co-cultivation of MSC and resting macrophages in a transwell cell
culture system. Pores with a size of 0.4 μm allow exchange of MSC-produced soluble factors from upper chamber (MSC) to lower chamber (Mo).
(B) Schematic overview of Mo to MSC-Mo transition induced by immunomodulatory (also in the figure) and growth factors released by MSC.
Arrows next to cytokines show up- (") or down- (#) regulation in MSC-Mo.
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or chronic tissue injury or disease [34]. One of these fac-
tors, PGE-2, induces myeloid-derived suppressor cells
from dendritic cells [35] ([36] N. Obermayer: The ONE
Study workshop 2012). Similarly, PGE-2 plays a role inFigure 2 Role of MSC in macrophage-mediated immune regulation in
phenotype by production of immunomodulatory and growth factors. This
activated immune cells and surrounding parenchymal cells. MSC thereby b
cellular immune response by generation of Tregs.the induction of MSC-Mo [21]. The production of PGE-
2 by MSC increases under inflammatory conditions [37],
suggesting an increased efficacy of MSC to induce regu-
latory Mo under conditions of injury. IL-10 is another
factor associated with the generation of myeloidsitu. MSC modulate resting macrophages to adapt a regulatory
effect of MSC is enhanced by pro-inflammatory cytokines, released by
lock Mo-mediated activation of parenchymal cells and decrease
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10 producing dendritic cells [38], but it is doubtful
whether it is involved in the induction of MSC-Mo.
There is controversy whether MSC secrete IL-10 but in
our hands levels of IL-10 secreted by MSC are neglect-
able [39]. Furthermore, IFN-γ, crucial for the formation
of regulatory Mo [40] ([41] P. Riquelme and J. Hutchin-
son: The ONE Study workshop 2012), does not seem to
be involved in the generation of MSC-Mo as MSC
hardly secrete this cytokine [39,42]. MSC do secrete,
however, a diversity of other factors of which several
may play a role in the induction of MSC-Mo.
Functionally, MSC-Mo resemble several other types of
myeloid-derived suppressor cells in some respects. Most
of these cell types secrete IL-10 while their expression of
pro-inflammatory cytokines like IL-6, TNF-α, and IL-12
is reduced. The expression profile of adhesion molecules
and the migratory properties of MSC-Mo are not yet
elucidated, however. MSC-Mo may differ considerably
from non-adherent myeloid-derived suppressor cells in
this respect ([43] C. Macedo: The ONE Study workshop
2012). In vivo, MSC-Mo are formed in tissues they have
infiltrated and where they are exposed to a cocktail of
cytokines provided by the stroma. Several types of
myeloid-derived suppressor cells that are induced by a
single or a small panel of cytokines may therefore come
together in the MSC-Mo. Better characterization of the
secretory profile of the stroma and the migration pat-
terns of macrophages after encounter with the stroma
will reveal more details on these interesting and poten-
tially clinically useful cells.
Conclusions
MSC provide macrophages with signals that stimulate
conversion to a regulatory phenotype. There are two
conceivable applications for the generation of MSC-Mo,
the first by inducing MSC-Mo through MSC therapy,
and the second by the induction of MSC-Mo by tissue-
resident MSC. Pre-clinical and clinical studies that aim
to use or target MSC in organ transplantation should
consider that MSC-Mo may have a vital role in mediat-
ing the effects of MSC.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EE and MJH wrote the manuscript. Both authors read and approved the final
manuscript.
Acknowledgements
This MSC-Mo review is part of a review series resulting from ‘The ONE study
workshop 2012 - suppressor APC cell therapy’, supported by the European
Commission (EU FP7-HEALTH ‘The ONE Study’, Project reference 260687 (11/
2010-10/2015)) and generously organized by Professor Geissler and Dr
Hutchinson, Regensburg. The authors thank Dr Christian Johnson for
proofreading the manuscript.Author details
1Department of Surgery, University Medical Center of Regensburg,
Franz-Josef-Strauss Allee 11, Regensburg, Germany. 2Department of Internal
Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Received: 26 April 2012 Accepted: 21 June 2012
Published: 28 September 2012References
1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD,
Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential
of adult human mesenchymal stem cells. Science 1999, 284:143–147.
2. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P,
Grisanti S, Gianni AM: Human bone marrow stromal cells suppress
T-lymphocyte proliferation induced by cellular or nonspecific mitogenic
stimuli. Blood 2002, 99:3838–3843.
3. da Silva Meirelles L, Chagastelles PC, Nardi NB: Mesenchymal stem cells
reside in virtually all post-natal organs and tissues. J Cell Sci 2006,
119:2204–2213.
4. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M,
Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK: Transplantability
and therapeutic effects of bone marrow-derived mesenchymal cells in
children with osteogenesis imperfecta. Nat Med 1999, 5:309–313.
5. Williams AR, Trachtenberg B, Velazquez DL, McNiece I, Altman P, Rouy D,
Mendizabal AM, Pattany PM, Lopera GA, Fishman J, Zambrano JP, Heldman
AW, Hare JM: Intramyocardial stem cell injection in patients with
ischemic cardiomyopathy: functional recovery and reverse remodeling.
Circ Res 2011, 108:792–796.
6. Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS, Cattaneo S,
Durand DJ, Fitton T, Kuang JQ, Stewart G, Lehrke S, Baumgartner WW,
Martin BJ, Heldman AW, Hare JM: Cardiac repair with intramyocardial
injection of allogeneic mesenchymal stem cells after myocardial
infarction. Proc Natl Acad Sci U S A 2005, 102:11474–11479.
7. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M,
Ringden O: Treatment of severe acute graft-versus-host disease with
third party haploidentical mesenchymal stem cells. Lancet 2004,
363:1439–1441.
8. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E,
Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A,
Fibbe W, Ringden O, Developmental Committee of the European Group for
Blood and Marrow Transplantation: Mesenchymal stem cells for treatment
of steroid-resistant, severe, acute graft-versus-host disease: a phase II
study. Lancet 2008, 371:1579–1586.
9. Donizetti-Oliveira C, Semedo P, Burgos-Silva M, Cenedeze MA,
Malheiros DM, Reis MA, Pacheco-Silva A, Camara NO: Adipose tissue-
derived stem cell treatment prevents renal disease progression. Cell
Transplant 2012 Feb 2, Epub ahead of print.
10. Semedo P, Palasio CG, Oliveira CD, Feitoza CQ, Goncalves GM,
Cenedeze MA, Wang PM, Teixeira VP, Reis MA, Pacheco-Silva A, Camara NO:
Early modulation of inflammation by mesenchymal stem cell after acute
kidney injury. Int Immunopharmacol 2009, 9:677–682.
11. Bouffi C, Bony C, Courties G, Jorgensen C, Noel D: IL-6-dependent PGE2
secretion by mesenchymal stem cells inhibits local inflammation in
experimental arthritis. PLoS One 2010, 5:e14247.
12. Kubo N, Narumi S, Kijima H, Mizukami H, Yagihashi S, Hakamada K,
Nakane A: Efficacy of adipose tissue-derived mesenchymal stem cells for
fulminant hepatitis in mice induced by concanavalin A. J Gastroenterol
Hepatol 2012, 27:165–172.
13. Popp FC, Eggenhofer E, Renner P, Slowik P, Lang SA, Kaspar H, Geissler EK,
Piso P, Schlitt HJ, Dahlke MH: Mesenchymal stem cells can induce
long-term acceptance of solid organ allografts in synergy with low-dose
mycophenolate. Transpl Immunol 2008, 20:55–60.
14. Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W, Bartholomew A, Garcia B,
Wang H: Infusion of mesenchymal stem cells and rapamycin synergize to
attenuate alloimmune responses and promote cardiac allograft
tolerance. Am J Transplant 2009, 9:1760–1772.
15. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D: Human bone
marrow stromal cells inhibit allogeneic T-cell responses by indoleamine
2,3-dioxygenase-mediated tryptophan degradation. Blood 2004,
103:4619–4621.
Eggenhofer and Hoogduijn Transplantation Research 2012, 1:12 Page 5 of 5
http://www.transplantationresearch.com/content/1/1/1216. Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Pescatori M, Stubbs AP,
van Ijcken WF, Dahlke MH, Eggenhofer E, Weimar W, Hoogduijn MJ:
Inflammatory conditions affect gene expression and function of human
adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol 2010,
162:474–486.
17. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R,
Pennesi G: Bone marrow mesenchymal progenitor cells inhibit
lymphocyte proliferation by activation of the programmed death 1
pathway. Eur J Immunol 2005, 35:1482–1490.
18. Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate
allogeneic immune cell responses. Blood 2005, 105:1815–1822.
19. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE: Mesenchymal
stem cells inhibit generation and function of both CD34 +−derived and
monocyte-derived dendritic cells. J Immunol 2006, 177:2080–2087.
20. Kim J, Hematti P: Mesenchymal stem cell-educated macrophages: a
novel type of alternatively activated macrophages. Exp Hematol 2009,
37:1445–1453.
21. Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzon IM, Nepomnaschy I,
Costa H, Canones C, Raiden S, Vermeulen M, Geffner JR: Mouse bone
marrow-derived mesenchymal stromal cells turn activated macrophages
into a regulatory-like profile. PLoS One 2010, 5:e9252.
22. Dayan V, Yannarelli G, Billia F, Filomeno P, Wang XH, Davies JE, Keating A:
Mesenchymal stromal cells mediate a switch to alternatively activated
monocytes/macrophages after acute myocardial infarction. Basic Res
Cardiol 2011, 106:1299–1310.
23. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K,
Robey PG, Leelahavanichkul K, Koller BH, Brown JM, Hu X, Jelinek I, Star RA,
Mezey E: Bone marrow stromal cells attenuate sepsis via prostaglandin E
(2)-dependent reprogramming of host macrophages to increase their
interleukin-10 production. Nat Med 2009, 15:42–49.
24. Lu W, Fu C, Song L, Yao Y, Zhang X, Chen Z, Li Y, Ma G, Shen C: Exposure
to supernatants of macrophages that phagocytized dead mesenchymal
stem cells improves hypoxic cardiomyocytes survival. Int J Cardiol 2012
April 2, Epub ahead of print.
25. Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre-Bosquet N,
Dormont D, Gras G: Macrophage activation switching: an asset for the
resolution of inflammation. Clin Exp Immunol 2005, 142:481–489.
26. Mosser DM: The many faces of macrophage activation. J Leukoc Biol 2003,
73:209–212.
27. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ,
Liao LM, Lin S, Sun JP: Effect on left ventricular function of intracoronary
transplantation of autologous bone marrow mesenchymal stem cell in
patients with acute myocardial infarction. Am J Cardiol 2004, 94:92–95.
28. Bang OY, Lee JS, Lee PH, Lee G: Autologous mesenchymal stem cell
transplantation in stroke patients. Ann Neurol 2005, 57:874–882.
29. Taupin P: OTI-010 Osiris Therapeutics/JCR Pharmaceuticals. Curr Opin
Investig Drugs 2006, 7:473–481.
30. Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB,
Verspaget HW, Kooy-Winkelaar EM, Koning F, Zwaginga JJ, Fidder HH,
Verhaar AP, Fibbe WE, van den Brink GR, Hommes DW: Autologous bone
marrow-derived mesenchymal stromal cell treatment for refractory
luminal Crohn’s disease: results of a phase I study. Gut 2010,
59:1662–1669.
31. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH: Immunomodulation by
mesenchymal stem cells: a potential therapeutic strategy for type 1
diabetes. Diabetes 2008, 57:1759–1767.
32. Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA,
Capelli C, Rambaldi A, Cassis P, Rizzo P, Cortinovis M, Marasa M, Golay J,
Noris M: Autologous mesenchymal stromal cells and kidney
transplantation: a pilot study of safety and clinical feasibility. Clin J Am
Soc Nephrol 2011, 6:412–422.
33. Tan J, Wu W, Xu X, Liao L, Zheng F, Messinger S, Sun X, Chen J, Yang S,
Cai J, Gao X, Pileggi A, Ricordi C: Induction therapy with autologous
mesenchymal stem cells in living-related kidney transplants: a
randomized controlled trial. JAMA 2012, 307:1169–1177.
34. Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators
of the immune system. Nat Rev Immunol 2009, 9:162–174.
35. Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P: Positive
feedback between PGE2 and COX2 redirects the differentiation of
human dendritic cells toward stable myeloid-derived suppressor cells.
Blood 2011, 118:5498–5505.36. Obermajer N, Kalinski P: Generation of myeloid-derived suppressor cells
using prostaglandin E2. Transplant Res 2012, 1:15.
37. Hoogduijn MJ, Popp F, Verbeek R, Masoodi M, Nicolaou A, Baan C,
Dahlke MH: The immunomodulatory properties of mesenchymal stem
cells and their use for immunotherapy. Int Immunopharmacol 2010,
10:1496–1500.
38. Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF,
Hauben E, Roncarolo MG: Differentiation of type 1 T regulatory cells (Tr1)
by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway.
Blood 2010, 116:935–944.
39. Engela AU, Baan CC, Peeters AM, Weimar W, Hoogduijn MJ: Interaction
between adipose-tissue derived mesenchymal stem cells and regulatory
T cells. Cell Transplant 2012 Apr 2, Epub ahead of print.
40. Hutchinson JA, Riquelme P, Geissler EK, Fandrich F: Human regulatory
macrophages. Methods Mol Biol 2011, 677:181–192.
41. Riquelme P, Geissler EK, Hutchinson JA: Alternative Approaches to Myeloid
Suppressor Cell Therapy in Transplantation: Comparing Regulatory
Macrophages to Tolerogenic DCs and MDSCs. Transplant Res 2012, 1:17.
42. Oh JY, Kim MK, Shin MS, Wee WR, Lee JH: Cytokine secretion by human
mesenchymal stem cells cocultured with damaged corneal epithelial
cells. Cytokine 2009, 46:100–103.
43. Macedo C, Turquist H, Metes D, Thomson AW: Immunoregulatory
properties of rapamycin-conditioned monocyte-derived dendritic cells
and their role in transplantation. Transplant Res 2012, 1:16.
doi:10.1186/2047-1440-1-12
Cite this article as: Eggenhofer and Hoogduijn: Mesenchymal stem cell-
educated macrophages. Transplantation Research 2012 1:12.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
